Format

Send to

Choose Destination
See comment in PubMed Commons below
Drug Discov Today. 2013 Mar;18(5-6):265-71. doi: 10.1016/j.drudis.2012.10.007. Epub 2012 Oct 23.

Four disruptive strategies for removing drug discovery bottlenecks.

Author information

1
Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina, NC 27526, USA. ekinssean@yahoo.com

Abstract

Drug discovery is shifting focus from industry to outside partners and, in the process, creating new bottlenecks. Technologies like high throughput screening (HTS) have moved to a larger number of academic and institutional laboratories in the USA, with little coordination or consideration of the outputs and creating a translational gap. Although there have been collaborative public-private partnerships in Europe to share pharmaceutical data, the USA has seemingly lagged behind and this may hold it back. Sharing precompetitive data and models may accelerate discovery across the board, while finding the best collaborators, mining social media and mobile approaches to open drug discovery should be evaluated in our efforts to remove drug discovery bottlenecks. We describe four strategies to rectify the current unsustainable situation.

PMID:
23098820
DOI:
10.1016/j.drudis.2012.10.007
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center